drugset / Trial / NCT00934089
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
RandomizedCrossoverSingle-blindTreatment
Summary
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients. Blood samples will be collected to measure the amount of active metabolite of PF-04217329 in the plasma following dosing.
Timeline
- Start
- 2010-01
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latanoprost | Small molecule | — | Topical |
| Subject | taprenepag isopropyl | Small molecule | — | Topical |